Cushing's Syndrome clinical trials at UCSF

1 research study open to eligible people

(PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients with Cushing's Disease
open to eligible people ages 6-17
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's disease.
San Francisco, California and other locations

Last updated: September 16, 2024